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Background
Raltegravir is the first integrase inhibitor to get into the
clinic and the MK-0518 Expanded Access Program
(EAP) started in Italy in 2007, so that most patients now
have an observation period of two years. Up to date a
few studies have described the durability of raltegravir-
containing regimen with a follow up of 96 weeks [1].
Methods
Patients from the MK0518 EAP were followed-up pro-
spectively since enrolment in the study. Clinical and
laboratory data were collected every 2 - 4 months after
commercial availability.
Results
Out of 250 patients enrolled in the MK0518 EAP in our
centres, 229 are still on the same regimen. The mean
follow up was 80 weeks. At the time of present analysis
(96 weeks) 133 patients were evaluated. Eighty-nine% of
these had HIV-RNA < 50 Cp/mmc. Two patients tem-
porarily stopped therapy, one developing the integrase
72I mutation plus 2 additional RT mutations, and both
stably resuppressed the virus with the same regimen.
Seven patients discontinued therapy due to virological
failure: primary mutations for integrases were detected
in all the samples (155H/N, 148H+140S, 143R) in addi-
tion to other mutations (157Q, 72I, 73V, 165I, 97A,
163R). Four patients with non-primary mutations
detected continued the same therapy maintaining viral
replication below 4000 copies/ml, with 1.9 log decrease
in HIV-RNA. One patient was lost to follow up, four
discontinued due gastrointestinal AEs and one for CK
elevation, while eight died during the observation per-
i o d ,4o fn o n - H o d g k i n ’s lymphoma (NHL), 1 of acute
myocardial infarction, 2 of end stage liver disease and 1
post-transplantation for HCV-related cirrhosis. The
immunological gain of the patients who remained on
therapy is good in a salvage setting: +230 CD4/mmc.
Conclusions
T h eM K 0 5 1 8E A Ps e e m st oh a v ec o n t r i b u t e di nar e l e -
vant measure to obtain full viral suppression for two
years in most of our salvage patients, with an important
immunologic gain and very few adverse events, in a
situation were active companion drugs were really diffi-
cult to find out (the overall mean GSS was <2). The
number of deaths (including NHL that represented the
cause of death for 50% of the cases) has not been related
to the drug regimen, but more likely to the advanced
stage of HIV infection.
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